Humanized Oncology and Autoimmune Disease Mouse Models for T-Cell Engager Evaluation
Sponsored by Gempharmatech
Thursday 11 June 2026
4pm BST, 11am EDT
Sponsor Webinar held on Zoom
Presented by Dr. Jun Wang, Senior Scientific Director
T-cell engagers (TCEs) are antibody-based therapeutics that redirect T cells to recognize and eliminate pathogenic cells. While TCEs have demonstrated strong therapeutic efficacy in clinical trials across oncology and autoimmune indications, traditional preclinical models often lack the relevant human drug targets and struggle to mimic the complexity of human immune responses. This creates a critical gap in the development of safer, more efficacious TCEs.
In this webinar, attendees will learn how GemPharmatech addresses this gap. It will cover:
1. The current landscape of TCE development
2. Human immune system mouse models
3. Genetically humanized mouse models
4. Strategies for using humanized mouse models in TCE efficacy and safety evaluation
SPEAKER BIO
Dr. Jun Wang, Senior Scientific Director
Dr. Jun Wang has over 15 years of experience in biomedical research. Prior to joining GemPharmatech, he served as an Associate Director of Research at Explora Biolabs/Charles River. He has extensive experience with genetically engineered mouse models for drug discovery in various therapeutic areas. Dr. Wang holds a Ph.D. in Developmental Neurobiology from the City of Hope and received his postdoctoral training in pediatric brain cancer research from the Sanford Burnham Prebys Medical Discovery Institute.
Regulatory Considerations to Immunotherapies - Approaches to innovations
Wednesday 1 July 2026
4-4.40pm UK time | 11-11.40am EST GMT (UTC +0)
Virtual Thought Leadership Session held on Zoom
AGENDA OVERVIEW
Regulatory Development and Approval Pathways for Immunotherapy Products
Regulatory strategy and agency engagement for immunotherapy products
- Preclinical stage
- Early stage interactions
- CMC considerations
Lessons learned from early stage development
Moderator: Livija Deban, Chief Scientific Officer, Prokarium
Panellists:
Callum Scott, Senior VP, Development, Scancell
Margareth Jorvid, Senior Partner, LSM Group / Life Science Management
THOUGHT LEADER & MODERATOR
Advancing CGT - Commercial & Regulatory Considerations
Wednesday 1 July 2026
3-3.50 pm UK time, 10 -10.50 am EST GMT (UTC +0)
Virtual Thought Leadership Session held on Zoom
AGENDA OVERVIEW
Date July 1, 3-3.50pm UK time
Advancing CGT – Commercial & Regulatory Considerations
Duration: 50 minutes
0–20 mins | Expert Interview
Commercialising CGT: lessons from development, manufacturing, supply chain and market readiness
A focused interview exploring how cell and gene therapies can move from development to commercial reality, including operational readiness, manufacturing strategy, supply chain complexity and market access considerations.
20–50 mins | Panel Discussion: Advancing CGT – Commercial & Regulatory Considerations
Confirmed Panelists:
- Amir Hefni, CEO, Resolution Therapeutics
- Ruben Rizzi, Senior Vice President, Global Regulatory Affairs, BioNTech
- Christopher Middendorf, Senior Director, Technical, Pharma & Biotech GxP Compliance, Hogan Lovells
Discussion points:
- Balancing innovation, regulation and speed to market
- Building scalable manufacturing, quality and compliance strategies
- Commercialising advanced therapies in a challenging funding and access environment
